Give families more time with their loved ones

The GI Cancer Institute’s ACTICCA-1 trial is studying the best treatment for patients with biliary tract cancer, known as cholangiocarcinoma.

Biliary tract cancer is a rare form of cancer – there are only a few hundred cases in Australia in total every year. This makes it more difficult to conduct research into the best way to treat it. As a result, patients with biliary tract cancer do not have as many effective treatment options available to them as patients with more common cancers.

Please donate now, your support will make a difference.

 


Share